Gilead and Galapagos announce Filgotinib meets primary endpoint in the phase 3 Finch 3 study in Methotrexate-naïve rheumatoid arthritis patients

Friday, March 29, 2019

Gilead Sciences and Galapagos announced Week 24 results of FINCH 3, an ongoing, randomized, double-blind, active-controlled Phase 3 study of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis. FINCH 3 evaluated filgotinib in combination with methotrexate and as monotherapy in MTX-naïve patients. The study achieved its primary endpoint in the proportion of patients achieving an American College of Rheumatology 20 percent response (ACR20) at Week 24. The proportion of patients achieving the primary endpoint of ACR20 response at Week 24 was significantly higher for filgotinib 200 mg plus MTX and filgotinib 100 mg plus MTX compared with MTX alone. 

Read more

Find your job at Leiden Bio Science Park: plenty of challenging jobs available.

Find a Job